Tofidence (FDA)

FDA label — Tofidence (TOCILIZUMAB) Účinná látka: TOCILIZUMAB Indikace: 1 INDICATIONS AND USAGE TOFIDENCE™ (tocilizumab-bavi) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.3 ) Patients 2 years of age and ol Kontraindikace: 4 CONTRAINDICATIONS TOFIDENCE is contraindicated in patients with known hypersensitivity to tocilizumab products [see Warnings and Precautions (5.6) ]. Known hypersensitivity to tocilizumab products. ( 4 )

{
  "obor": "rheumatology",
  "název": "Tofidence (FDA)",
  "indikace": [
    "Rheumatoid Arthritis (RA)",
    "Giant Cell Arteritis (GCA)",
    "Polyarticular Juvenile Idiopathic Arthritis (PJIA)"
  ],
  "language": "lang-en",
  "diagnosis": [
    "ra"
  ],
  "specialty": "rheumatology",
  "study_type": "rct",
  "evidence_level": "level-1",
  "kontraindikace": "Known hypersensitivity to tocilizumab products",
  "v6_autopublish": true,
  "clinical_impact": "high-impact",
  "jazyk_originálu": "lang-en",
  "účinná_látka": "TOCILIZUMAB",
  "practice_recommendation": "practice-change"
}